Live
FierceBiotechSarepta's big bet on Arrowhead's siRNA assets yields early dataFierceBiotechMerck, girding for Keytruda cliff, flies toward promising CML asset with $6.7B Terns acquisitionFierceBiotechTakeda targets $1.3B in cost savings in further restructuringFierceBiotechEndogenex nets $50M to carry intestinal diabetes procedure to the FDAFierceBiotechAfter ph. 2 readout, analysts herald 'best-in-class potential' for Maze kidney candidate as stock plummetsEndpoints NewsAfter tumultuous year, Sarepta plots rebound with early data on RNA therapiesEndpoints NewsBeam looks to accelerated approval for AATD base editing after promising updateThermo FisherThermo Fisher Scientific and SHL Medical Collaborate to Deliver Fully Integrated Drug-Device Solutio - pharmiweb.comEndpoints NewsBoehringer Ingelheim plans for dealmaking and R&D spending amid US price pressureBioPharma DiveSarepta sees early success with RNAi drugs from ArrowheadThermo FisherThermo Fisher completes $8.9B buyout of Clario - MedTech DiveEndpoints NewsNovo reports more triple-G data from China; Grifols plots IPO for biopharma unit
Endpoints News Jan 5, 2026

Zenas BioPharma’s Phase 3 autoimmune disease readout disappoints

Zenas BioPharma’s Phase 3 autoimmune disease readout disappoints

Original
Body unavailable. Use the original source.

Directory

59 All